[NCHHSTP] Expanding PrEP in Communities of Color (EPICC)

ICR 202309-0920-011

OMB: 0920-1423

Federal Form Document

Forms and Documents
Document
Name
Status
Form and Instruction
New
Form and Instruction
New
Form and Instruction
New
Form and Instruction
New
Form and Instruction
New
Form and Instruction
New
Form and Instruction
New
Form and Instruction
New
Form and Instruction
New
Form and Instruction
New
Form and Instruction
New
Form and Instruction
New
Form and Instruction
New
Form and Instruction
New
Form and Instruction
New
Form and Instruction
New
Form and Instruction
New
Form and Instruction
New
Form and Instruction
New
Supplementary Document
2023-10-31
Supplementary Document
2023-10-31
Supplementary Document
2023-10-31
Supplementary Document
2023-10-31
Supplementary Document
2023-10-31
Supplementary Document
2023-10-31
Supplementary Document
2023-10-31
Supplementary Document
2023-10-31
Supplementary Document
2023-10-31
Supplementary Document
2023-10-30
Supplementary Document
2023-10-30
Supplementary Document
2023-10-30
Supplementary Document
2023-10-30
Supplementary Document
2023-10-30
Supplementary Document
2023-10-30
Supporting Statement B
2023-10-30
Supporting Statement A
2023-10-30
ICR Details
202309-0920-011
Received in OIRA
HHS/CDC 0920-22GA
[NCHHSTP] Expanding PrEP in Communities of Color (EPICC)
New collection (Request for a new OMB Control Number)   No
Regular 10/31/2023
  Requested Previously Approved
36 Months From Approved
1,244 0
759 0
0 0

PrEP choices have been increasing with new drugs and formulations that will become available in the next few years, including the long-acting injectable PrEP drug CAB-LA. Educating healthcare providers about PrEP best practices, including recommended use of new PrEP drugs, will ensure the delivery of quality PrEP services in accordance with CDC guidelines, and increase the number of PrEP users. Evidence based tools are available to support PrEP initiation and use but have been underutilized. These tools will be implemented to help healthcare providers screen patients for PrEP indications; counsel them about PrEP choices and factors that are important in their choice of PrEP regimen; guide their selection of a PrEP regimen; and support their adherence to, and persistence with, PrEP. Implementation science methods will be used to evaluate the effectiveness of the education module and support tools.

None
None

Not associated with rulemaking

  88 FR 41623 06/27/2023
88 FR 62793 09/13/2023
No

19
IC Title Form No. Form Name
Aim 1 Provider Patient Interaction (Baseline and Final) 0920-22GA Att 4e_Aim1ProviderPatientInteraction
Aim 1 Provider Post-Training Survey 0920-22GA Att 4d_Aim1ProviderPostTrainingSurvey
Aim 1 Provider Pre- Training Survey 0920-22GA Att 4c_Aim1ProviderPreTrainingSurvey
Aim 1 Provider Training Contact Information 0920-22GA Att 4b_Aim1ProviderTrainingContactInformation
Aim 1 Provider Training Screener 0920-22GA Att 4a_Aim1ProviderTrainingScreener
Aim 2a Cohort App Setup (English/Spanish) 0920-22GA Att 4j_Aim2aCohortAppSetupEnglishSpanish
Aim 2a Cohort Baseline Survey (English/Spanish) 0920-22GA, 0920-22GA Att 4i_Aim2aCohortBaselineSurveyEnglish ,   Att 4i_Aim2aCohortBaselineSurveySpanish
Aim 2a Cohort Blood Collection Instructions (English/Spanish) 0920-22GA Att 4l_Aim2a Cohort Blood Collection Instructions English
Aim 2a Cohort Contact Information (English/Spanish) 0920-22GA Att 4b_Aim1ProviderTrainingContactInformation
Aim 2a Cohort Exit Interview (English/Spanish) 0920-22GA, 0920-22GA Att 4m_Aim2a Cohort Exit Interview English ,   Att 4m_Aim2aCohortExitInterviewSpanish
Aim 2a Cohort Follow-up Survey (English/Spanish) 0920-22GA, 0920-22GA Att 4k_Aim2aCohortFollowUpSurveyEnglish ,   Att 4k_Aim2aCohortFollowUpSurveySpanish
Aim 2a Cohort HIPAA Form (English & Spanish) 0920-22GA, 0920-22GA Att 4h_Aim2aCohortHIPAAFormEnglish ,   Att 4h_Aim2aCohortHIPAAFormSpanish
Aim 2a Cohort Screener (English/Spanish) 0920-22GA, 0920-22GA Att 4f_Aim2aCohortScreenerEnglish ,   Att 4f_Aim2aCohortScreenerSpanish
Aim 2b Provider Focus Group Contact Information 0920-22GA Att 4o_Aim2b Provider FocusGroup Contact Information
Aim 2b Provider Focus Group Guide 0920-22GA Att 4o_Aim2b Provider FocusGroup Contact Information
Aim 2b Provider Focus Group Screener 0920-22GA Att_4n_Aim2bProvider FocusGroup Screener
Aim 2b Provider Pre-Focus Group Survey 0920-22GA Att 4p_Aim2b Provider Pre FocusGroup Survey
Aims 1&2 Clinic Assessment (Baseline & Final) 0920-22GA Att 4r_Aim1&2ClinicAssessmentBaselineAndFinal
Aims 1&2 Clinic Assessment (every 6 months) 0920-22GA Aims 1&2 Clinic Assessment (every 6 months)

  Total Request Previously Approved Change Due to New Statute Change Due to Agency Discretion Change Due to Adjustment in Estimate Change Due to Potential Violation of the PRA
Annual Number of Responses 1,244 0 0 1,244 0 0
Annual Time Burden (Hours) 759 0 0 759 0 0
Annual Cost Burden (Dollars) 0 0 0 0 0 0
Yes
Miscellaneous Actions
No
This is a new collection requesting a total of 3,535 burden hours across 36 months of data collection. The total estimated annualized burden hours are 759.

$1,112,799
No
    No
    No
No
No
No
No
Odion Clunis 770 488-0045 lta2@cdc.gov

  No

On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
 
 
 
 
 
 
 
    (i) Why the information is being collected;
    (ii) Use of information;
    (iii) Burden estimate;
    (iv) Nature of response (voluntary, required for a benefit, or mandatory);
    (v) Nature and extent of confidentiality; and
    (vi) Need to display currently valid OMB control number;
 
 
 
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.
10/31/2023


© 2024 OMB.report | Privacy Policy